Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
A legfontosabb adatok
- Ki végzi
- National Institute of Allergy and Infectious Diseases (NIAID)
- Hol
- Ann Arbor és Bethesda (Egyesült Államok)Mind a 2 helyszín megnézéseMég 2 másik országban, 7 helyszínen
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 5000 fő, tervezett
- Kezdés
- 2007. febr. 12.
- A vizsgálat típusa
- Megfigyeléses
- A regiszteradat frissítve
- 2026. november 12.
Ki vehet részt
- Életkor
- 1 hónap – 100 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 3 feltétel megnézéseKevesebb
Ki nem vehet részt
- Severely debilitated health status or poor venous access may preclude obtaining adequate specimens for analysis. The minimum weight for infants on this protocol is 3 kg because of the limits of maximal acceptable blood draw volumes and minimum requirement for core laboratory tests would exceed the acceptable volume
- Co-enrollment guidelines: Participants may be co-enrolled in other studies including NIH protocols 05-I-0213, 93-I-0063 and 17-I-0122. Participants should inform the investigator of participation in other research studies
Egyéb feltételek
- INCLUSION CRITERIA:; Patients known to have or suspected of having an inherited immune cell homeostasis, programmed cell death susceptibility syndrome, lymphocyte developmental block, or defective immune cell effector functions will be eligible for enrollment. We will enroll; patients with suspected disease if the investigator agrees that there is a high index of suspicion. Blood relatives of enrolled patients will be eligible for enrollment. There will be no limit as to age, sex, race, or disability
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
Még 2 másik országban, 7 helyszínen
- University of MichiganAnn Arbor, Egyesült ÁllamokContact: Kelly Walkovich, M.D.Résztvevőt keres
- National Institutes of Health Clinical CenterBethesda, Egyesült ÁllamokContact: Helen C Su, M.D.Résztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study will determine the biochemical and genetic causes of inherited immune diseases affecting lymphocyte homeostasis. Lymphocytes are a type of white blood cell that fights infections. Normally, the body keeps a precise balance in which lymphocyte growth is matched by lymphocyte death. People with constantly enlarged lymph nodes or spleen, along with autoimmune disease, immunodeficiency, lymphoma, or other immune problems affecting lymphocytes may have an abnormality of the immune system in the cell growth and cell death processes that regulate lymphocyte homeostasis.
A teljes eredeti leírásKevesebb
Patients who have, or are suspected of having, an inherited lymphocyte homeostasis or programmed cell death susceptibility syndrome may be eligible for this study. Relatives of patients are also included.
Participants' (patients and relatives) medical records are reviewed and blood samples are drawn for studies to identify genes involved in immune disorders. Tissues that have been removed from patients for medical reasons, such as biopsied tissues, may be examined for tissue and DNA studies. Relatives are studied to determine if some of them may have a very mild form of lymphocyte homeostasis disorder.
Patients who have an immune problem that the researchers wish to study further will be invited to donate additional blood samples at irregular intervals (at least once a year) and to provide an update of their medical records at the same time.
A vizsgálat csoportja
- patients referred by physician with a suspected inherited immune deficiency
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- A regiszteradat frissítve
- 2026. november 12.